At this time, AI technology is not ready for clinical use. A number of people are working to improve the technology and assess its applicability in scientific studies.
However, the U.S. Food and Drug Administration (FDA) has granted the company Paige.AI a Breakthrough Device Designation. The designation is granted for technologies that have the potential to improve diagnostics or treatment for diseases such as cancer.
Paige.AI is developing machine learning algorithms to review digitized pathology slides and identify characteristics of benign and malignant tissue. Although the applications could be applied to all cancers, the company is starting with prostate cancer.